Health System

Results of a secondary analysis of a randomized controlled trial emphasize the risks of polypharmacy with regard to prescription and nonprescription medications.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Fine-tuning clinical phenotypes and identifying effective treatments remain challenging in chronic lung allograft dysfunction (CLAD) after lung transplantation and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.

New data show extreme heat waves were associated with higher all-cause mortality throughout the United States, with increased risks seen among men, the elderly, and non-Hispanic Black individuals.

The latest report from FAIR Health shows that the majority of people diagnosed post-COVID condition were never hospitalized.

Real-world patients with psoriasis demonstrated significant improvement in difficult-to-treat scalp, nail, palmoplantar, and genital disease manifestations with the IL-23 inhibitor tildrakizumab.

Ryan Haumschild PharmD, MS, MBA, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute, spoke with AJMC® about health care resource utilization and clinical decision support in the care of patients with small cell lung cancer (SCLC).

Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.

Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.

Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.

Dupilumab improved lung function and reduced severe asthma exacerbation rates in children with moderate to severe asthma with or without atopic comorbidities.

FDA to make an announcement regarding importation of baby formula; first-line use of nivolumab and ipilimumab vs standard of care chemotherapy fails to meet primary end point of overall survival in phase 3 CheckMate 901 trial; study finds link between antibiotic prescriptions and inflammatory bowel disease diagnosis in older adults.

Patients with psoriatic disease who live in low-income countries exhibited the highest disease activity and impact despite similar usage of biologic drugs to that of higher-income areas.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.

Veterans residing in rural areas were less likely to complete annual repeat lung cancer screenings compared with those living in a nonrural location, with reduced uptake of initial lung cancer screening also found among eligible veterans in rural vs nonrural locations.

Oral care decreased both the number of intensive care unit (ICU) patients and the length of stay, as well as the amount of time of mechanical ventilation.

Bimekizumab demonstrated a favorable long-term safety profile for the treatment of moderate to severe psoriasis, aside from an increased incidence of mild to moderate oral candidiasis that was also observed with short-term exposure.

Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.

COVID-19–related hospitalizations are up 17% week over week; an estimated 5 to 14 million Americans could lose their Medicaid coverage this year or next year; the CDC is investigating unexplained cases of severe hepatitis in children.

The latest Community Checkup report from the Washington Health Alliance reports on health care quality across Washington state.

The February drop out of the top 5 coincided with a sharp decline in new cases of COVID-19, as reported by the CDC, following the January peak of the wave of cases related to the Omicron variant.

US Senate to vote this week on legislation seeking to codify abortion rights into law; hospitals aiming to raise treatment prices in response to increasing nurse salaries; shortage of infant formula worsening nationwide.

Next-generation sequencing identified different molecular profiles of pediatric and adult sarcomas among Chinese patients.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on safety considerations for the use of Janus kinase (JAK) inhibitors in pediatric patients with atopic dermatitis.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

When it comes to making equity improvements and successes sustainable, leadership from the top levels are required, and that means finding champions who are bold, open to collaboration, and willing to explore new partnerships with an open mind, the panel agreed.

A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.

Future quality conversations must recognize what the pandemic has illustrated over the past 2 years—that patients who were in the most dire need of health care, including those with multiple chronic conditions, had the least amount of access, said Jonathan Blum, MPP, the principal deputy administrator and chief operating officer of CMS.